vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and SOLAREDGE TECHNOLOGIES, INC. (SEDG). Click either name above to swap in a different company.
SOLAREDGE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($335.4M vs $191.2M, roughly 1.8× Axsome Therapeutics, Inc.). On growth, SOLAREDGE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (70.9% vs 57.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 28.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
SolarEdge Technologies, Inc. is an Israeli company that developed a DC optimized inverter system.
AXSM vs SEDG — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $335.4M |
| Net Profit | — | $-132.1M |
| Gross Margin | — | 22.2% |
| Operating Margin | -33.1% | -14.4% |
| Net Margin | — | -39.4% |
| Revenue YoY | 57.4% | 70.9% |
| Net Profit YoY | — | 54.0% |
| EPS (diluted) | — | $-2.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $335.4M | ||
| Q3 25 | $171.0M | $340.2M | ||
| Q2 25 | $150.0M | $289.4M | ||
| Q1 25 | $121.5M | $219.5M | ||
| Q4 24 | $118.8M | $196.2M | ||
| Q3 24 | $104.8M | $235.4M | ||
| Q2 24 | $87.2M | $265.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-132.1M | ||
| Q3 25 | $-47.2M | $-50.1M | ||
| Q2 25 | $-48.0M | $-124.7M | ||
| Q1 25 | $-59.4M | $-98.5M | ||
| Q4 24 | $-74.9M | $-287.4M | ||
| Q3 24 | $-64.6M | $-1.2B | ||
| Q2 24 | $-79.3M | $-130.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.2% | ||
| Q3 25 | — | 21.2% | ||
| Q2 25 | — | 11.1% | ||
| Q1 25 | — | 8.0% | ||
| Q4 24 | — | -57.2% | ||
| Q3 24 | — | -309.1% | ||
| Q2 24 | — | -4.1% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -14.4% | ||
| Q3 25 | -27.0% | -10.3% | ||
| Q2 25 | -24.5% | -39.9% | ||
| Q1 25 | -46.9% | -46.8% | ||
| Q4 24 | -61.1% | -134.4% | ||
| Q3 24 | -59.8% | -471.8% | ||
| Q2 24 | -89.5% | -60.4% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -39.4% | ||
| Q3 25 | -27.6% | -14.7% | ||
| Q2 25 | -32.0% | -43.1% | ||
| Q1 25 | -48.9% | -44.9% | ||
| Q4 24 | -63.1% | -146.5% | ||
| Q3 24 | -61.7% | -522.8% | ||
| Q2 24 | -91.0% | -49.3% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-2.21 | ||
| Q3 25 | $-0.94 | $-0.84 | ||
| Q2 25 | $-0.97 | $-2.13 | ||
| Q1 25 | $-1.22 | $-1.70 | ||
| Q4 24 | $-1.54 | $-5.00 | ||
| Q3 24 | $-1.34 | $-21.58 | ||
| Q2 24 | $-1.67 | $-2.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $493.2M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $427.5M |
| Total Assets | $713.6M | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $493.2M | ||
| Q3 25 | $325.3M | $498.6M | ||
| Q2 25 | $303.0M | $758.0M | ||
| Q1 25 | $300.9M | $651.6M | ||
| Q4 24 | $315.4M | $585.9M | ||
| Q3 24 | $327.3M | $678.8M | ||
| Q2 24 | $315.7M | $689.8M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $427.5M | ||
| Q3 25 | $73.7M | $479.8M | ||
| Q2 25 | $73.1M | $513.2M | ||
| Q1 25 | $53.2M | $594.2M | ||
| Q4 24 | $57.0M | $658.3M | ||
| Q3 24 | $92.9M | $930.9M | ||
| Q2 24 | $102.9M | $2.1B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $2.2B | ||
| Q3 25 | $669.3M | $2.2B | ||
| Q2 25 | $639.8M | $2.5B | ||
| Q1 25 | $596.7M | $2.5B | ||
| Q4 24 | $568.5M | $2.6B | ||
| Q3 24 | $561.5M | $2.8B | ||
| Q2 24 | $548.2M | $3.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $52.6M |
| Free Cash FlowOCF − Capex | — | $43.3M |
| FCF MarginFCF / Revenue | — | 12.9% |
| Capex IntensityCapex / Revenue | — | 2.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $80.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $52.6M | ||
| Q3 25 | $1.0M | $25.6M | ||
| Q2 25 | $-32.4M | $-7.8M | ||
| Q1 25 | $-43.4M | $33.8M | ||
| Q4 24 | $-26.2M | $37.8M | ||
| Q3 24 | $-18.6M | $-89.3M | ||
| Q2 24 | $-30.1M | $-44.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $43.3M | ||
| Q3 25 | $988.0K | $22.8M | ||
| Q2 25 | $-32.4M | $-9.1M | ||
| Q1 25 | $-43.7M | $23.7M | ||
| Q4 24 | $-26.2M | $25.5M | ||
| Q3 24 | $-18.7M | $-136.7M | ||
| Q2 24 | $-30.2M | $-67.0M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 12.9% | ||
| Q3 25 | 0.6% | 6.7% | ||
| Q2 25 | -21.6% | -3.1% | ||
| Q1 25 | -36.0% | 10.8% | ||
| Q4 24 | -22.1% | 13.0% | ||
| Q3 24 | -17.9% | -58.1% | ||
| Q2 24 | -34.6% | -25.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 2.8% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.3% | 4.6% | ||
| Q4 24 | 0.0% | 6.2% | ||
| Q3 24 | 0.1% | 20.1% | ||
| Q2 24 | 0.1% | 8.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
SEDG
| Other | $197.7M | 59% |
| Europe Except Netherlands | $99.4M | 30% |
| Others | $38.2M | 11% |
